1. Evered JA, LaJeunesse A, Wynn M, Mrig E, Schlesinger M, Grob R. Gaps in benefits, awareness, and comprehension that leave those with long COVID vulnerable. Chronic Illn. 2023 Oct 30:17423953231210117. doi: 10.1177/17423953231210117. Epub ahead of print. PMID: 37899735.
  2. Sahin-Hodoglugil NN, Lianoglou BR, Ackerman S, Sparks TN, Norton ME. Access to prenatal exome sequencing for fetal malformations: A qualitative landscape analysis in the US. Prenat Diagn. 2023 Sep 26. doi: 10.1002/pd.6444. Epub ahead of print. PMID: 37752660.
  3. Jansen JP, Ragavan MV, Chen C, Douglas MP, Phillips KA. The health inequality impact of liquid biopsy to inform first-line treatment of advanced non-small cell lung cancer - a distributional cost-effectiveness analysis. Value Health. 2023 Sep 21:S1098-3015(23)03126-1. doi: 10.1016/j.jval.2023.08.010. Epub ahead of print. PMID: 37741446.
  4. Lin GA, Phillips KA, Fendrick AM. Reading the crystal ball: Primary care implications while awaiting outcomes for multi-cancer early detection tests. Healthc (Amst). 2023 Aug 18;11(3):100705. doi: 10.1016/j.hjdsi.2023.100705. Epub ahead of print. PMID: 37598614.
  5. Douglas MP, Ragavan MV, Chen C. Kumar A, Gray SW, Blakely CM, Phillips KA. Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment. Journal of the National Comprehensive Cancer Network, 21(6), 609-616.e4. Retrieved Jul 6, 2023, from
  6. Phillips, Kathryn A., Deborah A. Marshall, Loren Adler, Jose Figueroa, Simon F. Haeder, Rita Hamad, Inmaculada Hernandez, Corrina Moucheraud, and Sayeh Nikpay. "Ten health policy challenges for the next 10 years." Health Affairs Scholar 1, no. 1 (2023): qxad010.
  7. Trosman JR, Weldon CB, Kurian AW, Pasquinelli MM, Kircher SM, Martin N, Douglas MP, Phillips KA. Perspectives and evidence needs of private payers for multicancer early detection tests: informing research, clinical implementation, and the policy agenda. Health Affairs Scholar. Volume 1, Issue 1, July 2023, qxad005,
  8. Mrig, E. HPR87 Patient Assistance Programs for Genetic Testing: Closing the Underinsurance Gap or Widening Disparities?, Value in Health, Volume 26, Issue 6, Supplement, June 2023, Page S227, ISSN 1098-3015,
  9. Chen C, Roberts MH, Raisch DW, Thompson TA, Bachyrycz A, Borrego ME. Preferences for pharmacogenomic testing in polypharmacy patients: a discrete choice experiment. Per Med. 2022 Nov 1. doi: 10.2217/pme-2022-0056. Epub ahead of print. PMID: 36317592.
  10. Phillips KA - How CMS “Coverage with Evidence Development” Reflects Opportunities & Challenges for Value-Based Care. JAMA Health Forum 2022;3(9):e223061.
  11. Weldon CB, Trosman JR, Liang S-Y, Douglas MP, Scheuner MT, Kurian AW, Schaa K, Roscow B, Erwin D, Phillips KA. Genetic Counselors’ experience with reimbursement and patient out-of-pocket cost for multi-cancer gene panel testing for hereditary cancer syndromes. J Genet Couns. 2022; 31:1394-1403. PMID: 35900261.
  12. Arias JJ, Lin GA, Tyler AM, Douglas MP, Phillips KA. Geriatricians' Perspectives on the Multiple Dimensions of Utility of Genetic Testing for Alzheimer's Disease: A Qualitative Study. J Alzheimers Dis. 2022;90(3):1011-1019.PMID: 35871355.
  13. Jansen JP, Trikalinos TA, Phillips KA. Assessments of the Value of New Interventions Should Include Health Equity Impact. Pharmacoeconomics. 2022 May;40(5):489-495.
  14. Douglas MP, Kumar A. Analyzing Precision Medicine Utilization with Real-World Data: A Scoping Review. Journal of Personalized Medicine. 2022; 12(4): 557. PMID: 35455673.
  15. Deverka PA, Douglas MP, Phillips KA. Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access. Health Affairs. 2022: 41(3): 383-389.
  16. Jansen JP, Linthicum M, Chapman RH. Value Assessment And Decision Making In The Face Of Uncertainty. Health Affairs Forefront. January 26, 2022.
  17. Phillips KA, Redberg RF. Medicare “Coverage with Evidence Development” Leaps into the Spotlight with CMS Draft National Coverage Decision on Alzheimer’s Drugs. Health Affairs Forefront. January 25, 2022.
  18. Phillips KA. CMS Coverage With Evidence Development-Challenges and Opportunities for Improvement. JAMA Health Forum. 2022 Sep 2;3(9):e223061. PMID: 36218935. NIHMS: 1858978.
  19. Thom H, Leahy J, Jansen JP. Network Meta-analysis on Disconnected Evidence Networks When Only Aggregate Data Are Available: Modified Methods to Include Disconnected Trials and Single-Arm Studies while Minimizing Bias. Medical Decision Making. May 2022. doi:10.1177/0272989X221097081
  20. Douglas MP, Lin GA, Trosman JR, Phillips KA. Hereditary cancer panel testing challenges and solutions for the Latinx community: costs, access, and variants. J Community Genet. 2022;13(1):75-80.
  21. Phillips KA, Trosman JR, Douglas MP, Gelb BD, Ferket BS, Hindorff LA, Slavotinek AM, Berg JS, Russell HV, Devine B, Greve V, Smith HS. US private payers' perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER). Genet Med. 2022;24(1):238-244.
  22. Lin GA, Trosman JR, Douglas MP, Weldon CB, Scheuner MT, Kurian A, Phillips KA. Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. J Genet Couns. 2022; 31:130–139.
  23. Jansen JP. Evidence Synthesis Methods to Estimate Subgroup Effects for Distributional Cost-effectiveness Analysis of New Treatments, 15 November 2021, PREPRINT (Version 3), Research Square
  24. Arias JJ, Phillips KA, Karlawish J. Developing an Economic and Policy Research Agenda for Blood Biomarkers of Neurodegenerative Diseases. JAMA Health Forum. 2021;2(7):e211428.
  25. Scheuner MT, Douglas MP, Sales P, Ackerman SL, Phillips KA. Laboratory business models and practices: Implications for availability and access to germline genetic testing. Genet. Med. 2021;23:1681–1688.
  26. Phillips KA, Douglas MP, Wordsworth S, Buchanan J, Marshall DA. Availability and funding of clinical genomic sequencing globally. BMJ Global Health. 2021;6:e004415.
  27. Phillips KA. The Coming Era Of Precision Health. Health Affairs Blog. Published online February 4, 2021.
  28. Phillips KA, Jansen JP, Weyant CF. Value and Affordability in Precision Medicine. Science. 2021;371(6529): 564-569.
  29. Arias JJ, Tyler AM, Douglas MP, Phillips KA. Private Payer Coverage Policies for ApoE4 Genetic Testing. Genet Med. 2021;23:614-620.
  30. Jansen JP, Incerti, D, Trikalinos T. Multi-state network meta-analysis of cause-specific survival data. medRxiv 2020.11.13.20231332; doi:
  31. Phillips KA, Douglas MP, Marshall DA. Expanding Use of Clinical Genome Sequencing and the Need for More Data on Implementation. JAMA. 2020 Nov 24;324(20):2029-2030. doi: 10.1001/jama.2020.19933. PMID: 33104159; PMCID: PMC7686292..
  32. Douglas MP, Gray SW, Phillips KA. Private Payer and Medicare Coverage Policies for Circulating Tumor DNA Testing in Cancer Patients: Trends from 2015-2019. J Natl Compr Canc Netw. 2020;18(7)866-872.
  33. Phillips KA. Introduction to Themed Papers: Methods for Moving Evaluation of Precision Medicine into Practice and Policy. Value Health. 2020;23(5):527-528.
  34. Marshall DA, Grazziotin L, Regier DA, Wordsworth S, Buchanan J, Phillips KA, Ijzerman M.Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling. Value Health. 2020;23(5):566-573.
  35. Mackay Z, Dukhovny D, Parad RB, Phillips KA, Beggs AH, Green RB, Christensen KD. Quantifying Downstream Health Care Utilization in Studies of Genomic Testing. Value Health. 2020;23(5):559-565.
  36. Trosman JR, Douglas MP, Liang S, Weldon CB, Kurian AW, Kelley RK, Phillips KA. Insights from a Temporal Assessment of Increases in U.S. Private Payer Coverage of Tumor Sequencing from 2015 to 2019. Value Health. 2020;23(5):551-558.
  37. Deverka PA, Douglas MP, Phillips KA. Use of Real World Evidence in U.S. Payer Coverage Decision-making for NGS-based Tests: Challenges, Opportunities, and Potential Solutions. Value Health. 2020;23(5):540-550.
  38. Phillips KA, Deverka PA. “Policy Implications of Commercial Payer Use of Third Party Benefit Managers: The Example of the Emerging Role of Lab Benefit Managers for Genetic Testing” Health Affairs Blog.
  39. Trosman JR, Weldon CB, Slavotinek A, Norton ME, Douglas MP, Phillips KA. Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS). Genet Med.2020;22(2): 283-291.
  40. Phillips KA, Trosman JR, Douglas MP. Emergence of Hybrid Models of Genetic Testing Beyond Direct-to-Consumer or Traditional Labs. JAMA. 2019;321(24):2403-2404.
  41. Phillips KA, Kroon LA, Bibbins-Domingo K, Douglas MP, Reyes KL. Pharmacies for Covid-19 Care. Public Health Post.
  42. Douglas MP, Parker SL, Trosman JR, Slavotinek AM, Phillips KA. Private Payer Coverage Policies for Exome Sequencing (ES) in Pediatric Patients: Trends Over Time and Analysis of Evidence Cited. Genet. Med. 2019;21(1):152-160 (PMCID: PMC6329652)
  43. Phillips KA, Douglas MP. The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace. Journal Precision Medicine, 2018.
  44. Phillips KA, Trosman JR, Weldon CB, Douglas MP. The New Medicare Coverage Policy for Next Generation Tumor Sequencing: A Key Shift in Coverage Criteria with Broad Implications beyond Medicare. JCO Precis Oncol. 2018 :2, 1-5.
  45. Phillips KA. Assessing the Value of Next-Generation Sequencing Technologies: An Introduction. Value Health. 2018; 21(9):1031-1032.
  46. Phillips KA, Deverka PA, Marshall DA, Wordsworth S, Regier DA, Christensen KD, Buchanan J. Methodological Challenges and Solutions for Assessing Economic Value of Next Generation Sequencing Tests. Value Health. 2018; 21(9):1033-1042.
  47. Wordsworth S, Doble B, Payne K, Buchanan J, Marshall DA, McCabe C, Regier DA. Using ‘big’ data in the cost-effectiveness analysis of genomic-based diagnostic tests: challenges and potential solutions. Value Health. 2018; 21(9):1048-1053.
  48. Reiger DA, Weymann D, Buchanan J, Marshall DA, Wordsworth S. Valuation of health and non-health Outcomes from Next-Generation Sequencing: Approaches, Challenges, and Solutions. Value Health 2018; 21(9):1043-1047.
  49. Christensen KD, Phillips KA, Green RC, Dukhovny D. Cost Analyses of Genomic Sequencing – Lessons Learned from the MedSeq Project. Value Health. 2018; 21(9):1054-1061.
  50. Trosman JR, Weldon CB, Gradishar WJ, Benson AB III, Cristofanilli M, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA. From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value Health. 2018; 21(9):1062-1068.
  51. Phillips KA, Deverka PA, Hooker GW, Douglas MP. Genetic Test Availability And Spending: Where Are We Now? Where Are We Going? Health Aff (Millwood). 2018;37(5):710-716. (PMCID: PMC5987210)
  52. Ginsburg GS, Phillips KA. Precision Medicine: From Science to Value. Health Aff (millwood). 2018;37(5):694-701. (PMCID: PMC5989714)
  53. Christensen KD, Vassy JL, Phillips KA, Blout CL, Azzariti DR, Lu CY, Robinson JO, Lee K, Douglas MP, Yeh JM, Machini K, Stout NK, Rehm HL, McGuire AL, Green RC, Dukhovny D. Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genet Med. 2018;20(12):1544-1553. Mar 22 (PMCID: PMC6151171)
  54. Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP Jr., Douglas MP, Weldon CB. Insurance coverage for genomic tests. Science. 2018; 360(6386):278-279. (PMCID: PMC5991085)
  55. Phillips KA. Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA. 2018; 319(23):2379-2380. (PMCID: PMC6013401)
  56. Phillips KA and Subhashini Chandrasekharan. At The Prospect Of Delivering A Child With A Genetic Disorder, Poorer Women May Have Less Information and Fewer Choices. Health Affairs Blog. 12/19/2017. 10.1377/HBLOG20171215.457066
  57. Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw. 2017; Feb;15(2):219-228. (PMCID: PMC5508568)
  58. Dervan AP, Deverka PA, Trosman JR, Weldon CB, Douglas MP, and Phillips KA. Payer Decision-Making for Next Generation Sequencing-Based Genetic Tests: Insights from Cell-Free DNA Prenatal Screening. Genet Med, 2017; May;19(5):559-567. (PMCID: PMC5362360)
  59. Marshall DA, Gonzalez JM, MacDonald KV, et al. Estimating Preferences for Complex Health Technologies: Lessons Learned and Implications for Personalized Medicine. Value Health. 2017;20(1): 32-39. (PMCID: PMC5319756)
  60. Phillips KA, Douglas MP, Trosman JR, et al. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine. Value Health. 2017;20(1): 47-53. (PMCID: PMC5319740)
  61. Trosman JR, Weldon CB, Douglas MP, et al. Decision-Making on Medical Innovations in a Changing Health Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. Value Health. 2017;20(1): 40-46. (PMCID: PMC5319741)
  62. Marshall DA, MacDonald KV, Oliver Robinson J, Barcellos LF, Gianfrancesco M, Helm M, McGuire A, Green RC, Douglas MP, Goldman MA, Phillips KA. The price of whole genome sequencing may be decreasing, but who will be sequenced? Personalized Medicine, 2017; 14(2): 203-211. (PMCID: PMC5629976)
  63. Phillips KA, Deverka PA, Sox HC, Khoury MJ, Sandy LG, Ginsburg GS, Tunis SR, Orlando LA, Douglas MP. Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genet Med. 2017; 19:1081-1091. (PMCID: PMC5629101)
  64. Chambers JD, Saret CJ, Anderson JA, Deverka PA, Douglas MP, Phillips KA. Examining payer coverage policies for multi-gene panels and sequencing technology. Int J Technol Assess Health Care. 2017 Oct 25:1-7. (PMCID: PMC5732073)
  65. Phillips KA, Deverka PA, Trosman JR, Douglas MP, Chambers JD, Weldon CB, Dervan AP. Payer coverage policies for multigene tests. Nat Biotechnol. 2017 Jul 12;35(7):614-617. (PMCID: PMC5553867)
  66. Lu CY. Economic evaluation of gene panels and sequencing technologies: what can we learn from CEAs of whole-body CT screening? Genet Med. 2016 Jan;18(1):103-4. (PMCID: in process)
  67. Payne K, Redekop K, and Phillips KA. (2016) Personalized Medicine: Economic Evaluation and Evidence (book chapter). In World Scientific Handbook of Global Health Economics and Public Policy, Vol. 2, edited by Richard M. Scheffler. World Scientific, Imperial College Press. Hackensack, NJ.
  68. Phillips KA, Schleifer D, Hagelskamp C. Most Americans Do Not Believe That There Is An Association Between Health Care Prices And Quality Of Care. Health Affairs. 2016, 35:647-653. (PMCID: PMC5029784)
  69. Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips KA. Who decides and what are people willing-to-pay for whole genome sequencing information? Genet Med. 2016; Dec;18(12):1295-1302. (PMCID: PMC5133139)
  70. Douglas MP, Ladabaum U, Pletcher MJ, Marshall DA, Phillips KA. Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Genet Med. 2016 Feb;18(2):111-6. (PMCID: PMC4654986)
  71. Garfield S, Douglas MP, MacDonald KV, Marshall DA, and Phillips K A. Consumer familiarity, perspectives, and expected value of personalized medicine with a focus on applications in oncology. Personalized Medicine. 2015. 12(1):13-22 (PMCID: PMC4303575)
  72. Clain E, Trosman JR, Douglas MP, Weldon CB, and Phillips KA. Availability and payer coverage of BRCA1/2 tests and gene panels. Nat Biotechnol. 2015. 33(9):900-2. (PMCID: PMC4625918)
  73. Phillips KA, Ladabaum U, Pletcher MJ, Marshall DA, Douglas MP. Key emerging themes for assessing the cost-effectiveness of reporting incidental findings. Genet Med. 2015. 17(4):314-5. (PMCID: PMC4395812)
  74. Trosman JR, Weldon CB, Kelley RK, Phillips KA. Challenges of coverage policy development for next-generation tumor sequencing panels: Experts and Payers Weigh in. JNCCN. 2015. 13(3):311-8. (PMCID: PMC4372087)
  75. Phillips KA, Pletcher MJ, Ladabaum U. Is the “$1000 Genome” Really $1000? Understanding the Full Benefits and Costs of Genomic Sequencing. Technol Health Care 2015. 23(3)373-379. (PMCID: PMC4527943)
  76. Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer 2015. 15:206. (PMCID: PMC4399150)
  77. Deverka PA, Haga SB. Comparative effectiveness research and demonstrating clinical utility for molecular diagnostic tests. Clin Chem. 2015 61(1):142-4. (PMCID: PMC4454379)
  78. Phillips, KA; Sakowski JA; Trosman, J; Douglas, MP; Liang S; and Neumann, P. The Economic Value of Personalized Medicine: What We Know and What We Need to Know. Genet Med. 2014. Mar;16(3):251-7. (PMCID: PMC3949119)
  79. Phillips, K. A., J. R. Trosman, R. K. Kelley, M. J. Pletcher, M. P. Douglas and C. B. Weldon Genomic sequencing: assessing the health care system, policy, and big-data implications. Health Affairs. 2014. 33(7): 1246-1253. (PMCID: PMC4113721)
  80. Julian C. Schink, MD, Julia R. Trosman, PhD, Christine B. Weldon, MBA, Kalliopi P. Siziopikou, MD, PhD, Gregory J. Tsongalis, PhD, Alfred W. Rademaker, PhD, Jyoti D. Patel, MD, Al B. Benson III, MD, Edith A. Perez, MD, William J. Gradishar, MD. Biomarker Testing for Breast, Lung, and Gastroesophageal Cancers at NCI Designated Cancer Centers. JNCI J Natl Cancer Inst.2014. 106(10): Advance Online Publication September 2014. (PMCID: PMC4176043)
  81. Phillips, KA; and Labno A. Private Companies Providing Health Care Price Data: Who Are They and What Information do They Provide? 2014. JMCM. 17(4):75-80. (PMCID: PMC4323083)
  82. Phillips, K. A. and L. A. (2014). "“SHINING A LIGHT” on Companies Providing Healthcare Price Transparency Data. ." JMCM 17(4): 75-79.
  83. Trosman, J. R., C. B. Weldon, J. C. Schink, W. J. Gradishar and A. B. Benson, 3rd (2013). "What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer." J Comp Eff Res 2(4): 461-477.
  84. Shin, J., S. Y. Liang, M. J. Hassett, K. A. Phillips and J. S. Haas (2013). "Utilization of cardiac monitoring tests in women with non-metastatic breast cancer treated with trastuzumab." Personalized Medicine 10(7): 703-708.
  85. Phillips, K. A., J. S. Sakowski, S. Y. Liang and N. A. Ponce (2013). "Economic Perspectives on Personalized Health Care and Prevention. ." Forum for Health Economics and Policy. 16(2): S23-S52.
  86. Kuppermann, M., G. Wang, S. Wong, A. Blanco, P. Conrad, S. Nakagawa, J. Terdiman and U. Ladabaum (2013). "Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome." Cancer 119(1): 215-225.
  87. Ferrusi, I. L., C. C. Earle, M. Trudeau, N. B. Leighl, E. Pullenayegum, H. Khong, J. S. Hoch and D. A. Marshall (2013). "Closing the personalized medicine information gap: HER2 test documentation practice." Am J Manag Care 19(1): 838-844. PMCID: 3919466.
  88. Weldon, C. B., J. R. Trosman, W. J. Gradishar, A. B. Benson, 3rd and J. C. Schink (2012). "Barriers to the use of personalized medicine in breast cancer." J Oncol Pract 8(4): e24-31. PMCID: 3396824.
  89. Wang, G., M. Kuppermann, B. Kim, K. A. Phillips and U. Ladabaum (2012). "Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome." Am J Manag Care 18(5): e179-185.
  90. Wang, G., M. Kuppermann, B. Kim, K. A. Phillips and U. Ladabaum (2012). "Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome." J Oncol Pract 8(3 Suppl): e24s-30s. PMCID: 3348599.
  91. Walsh, J., M. Arora, C. Hosenfeld, U. Ladabaum, M. Kuppermann and S. J. Knight (2012). "Preferences for genetic testing to identify hereditary colorectal cancer: perspectives of high-risk patients, community members, and clinicians." J Cancer Educ 27(1): 112-119.
  92. Ponce, N. A., J. Tsui, S. J. Knight, A. Afable-Munsuz, U. Ladabaum, R. A. Hiatt and J. S. Haas (2012). "Disparities in cancer screening in individuals with a family history of breast or colorectal cancer." Cancer 118(6): 1656-1663. PMCID: 3262934.
  93. Ladabaum, U. and J. M. Ford (2012). "Lynch syndrome in patients with colorectal cancer: finding the needle in the haystack." JAMA 308(15): 1581-1583.
  94. Kelley, R. K., C. Atreya, A. P. Venook and P. G. Febbo (2012). "Predictive biomarkers in advance of a companion drug: ahead of their time?" J Natl Compr Canc Netw 10(3): 303-309.
  95. Beattie, M. S., G. Wang and K. A. Phillips (2012). "Differences in US healthcare coverage policies in BRCA testing and potential implications." Personalized Medicine. 9(1): 5-8.
  96. Wang, G., M. S. Beattie, N. A. Ponce and K. A. Phillips (2011). "Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling." Genet Med 13(12): 1045-1050.
  97. Trosman, J. R., S. L. Van Bebber and K. A. Phillips (2011). "Health technology assessment and private payers's coverage of personalized medicine." Am J Manag Care 17 Suppl 5 Developing: SP53-60.
  98. Trosman, J. R., S. L. Van Bebber and K. A. Phillips (2011). "Health technology assessment and private payers' coverage of personalized medicine." J Oncol Pract 7(3 Suppl): 18s-24s. PMCID: 3092460.
  99. Trosman JR, Van Bebber SL, Phillips KA. Health technology assessment and private payers's coverage of personalized medicine. Am J Manag Care. 2011 May;17 Suppl 5 Developing:SP53-60. PMID: 21711078.
  100. Pletcher, M. J. and M. Pignone (2011). "Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact." Circulation 123(10): 1116-1124. PMCID: 3138723.
  101. Odierna, D. H., A. Afable-Munsuz, O. Ikediobi, M. Beattie, S. Knight, M. Ko, A. Wilson and N. A. Ponce (2011). "Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes?" Per Med 8(6): 669-679. PMCID: 3242007.
  102. Lorizio, W., H. Rugo, M. S. Beattie, S. Tchu, T. Melese, M. Melisko, A. H. Wu, H. J. Lawrence, M. Nikoloff and E. Ziv (2011). "Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment." Genome Med 3(10): 64. PMCID: 3239226.
  103. Liang, S. Y., K. A. Phillips, G. Wang, C. Keohane, J. Armstrong, W. M. Morris and J. S. Haas (2011). "Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer." Med Care 49(6): e1-8. PMCID: 3383782.
  104. Ladabaum, U., G. Wang, J. Terdiman, A. Blanco, M. Kuppermann, C. R. Boland, J. Ford, E. Elkin and K. A. Phillips (2011). "Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis." Ann Intern Med 155(2): 69-79. PMCID: 3793257.
  105. Kelley, R. K., G. Wang and A. P. Venook (2011). "Biomarker use in colorectal cancer therapy." J Natl Compr Canc Netw 9(11): 1293-1302. PMCID: 3696980.
  106. Kelley, R. K. and A. P. Venook (2011). "Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?" Clin Colorectal Cancer 10(2): 73-80. PMCID: 3561586.
  107. Kelley, R. K., S. L. Van Bebber, K. A. Phillips and A. P. Venook (2011). "Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer." J Natl Compr Canc Netw 9(1): 13-25. PMCID: 3695822.
  108. Johnson, F. R., A. F. Mohamed, S. Ozdemir, D. A. Marshall and K. A. Phillips (2011). "How does cost matter in health-care discrete-choice experiments?" Health Econ 20(3): 323-330. PMCID: 3918954.
  109. Haas, J. S., K. A. Phillips, S. Y. Liang, M. J. Hassett, C. Keohane, E. B. Elkin, J. Armstrong and M. Toscano (2011). "Genomic testing and therapies for breast cancer in clinical practice." Am J Manag Care 17(5 Spec No): e174-181.
  110. Haas, J. S., K. A. Phillips, S. Y. Liang, M. J. Hassett, C. Keohane, E. B. Elkin, J. Armstrong and M. Toscano (2011). "Genomic testing and therapies for breast cancer in clinical practice." J Oncol Pract 7(3 Suppl): e1s-7s. PMCID: 3092459.
  111. Haas, J. S., S. Y. Liang, M. J. Hassett, S. Shiboski, E. B. Elkin and K. A. Phillips (2011). "Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care." Breast Cancer Res Treat 130(2): 619-626. PMCID: 3590013.
  112. Ferrusi, I. L., N. B. Leighl, N. A. Kulin and D. A. Marshall (2011). "Do economic evaluations of targeted therapy provide support for decision makers?" Am J Manag Care 17 Suppl 5 Developing: SP61-70. PMCID: 3918963.
  113. Ferrusi, I. L., N. B. Leighl, N. A. Kulin and D. A. Marshall (2011). "Do economic evaluations of targeted therapy provide support for decision makers?" J Oncol Pract 7(3 Suppl): 36s-45s. PMCID: 3092467.
  114. Elkin, E. B., D. A. Marshall, N. A. Kulin, I. L. Ferrusi, M. J. Hassett, U. Ladabaum and K. A. Phillips (2011). "Economic evaluation of targeted cancer interventions: critical review and recommendations." Genet Med 13(10): 853-860. PMCID: 3774033.
  115. Arar, N., S. J. Knight, S. M. Modell and A. M. Issa (2011). "The Genome-based Knowledge Management in Cycles model: a complex adaptive systems framework for implementation of genomic applications." Personalized Medicine. 8(2): 191-205.
  116. Wang, G., R. K. Kelley and Gappnet (2010). "KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic." PLoS Curr 2. PMCID: 2940138.
  117. Van Bebber, S. L., J. R. Trosman, S. Y. Liang, G. Wang, D. A. Marshall, S. Knight and K. A. Phillips (2010). "Capacity building for assessing new technologies: approaches to examining personalized medicine in practice." Per Med 7(4): 427-439. PMCID: 3157083.
  118. Trosman, J. R., S. L. Van Bebber and K. A. Phillips (2010). "Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay." J Oncol Pract 6(5): 238-242. PMCID: 2936466.
  119. Marshall, D., S. E. McGregor and G. Currie (2010). "Measuring Preferences for Colorectal Cancer Screening: What are the Implications for Moving Forward?" Patient 3(2): 79-89.
  120. Ladabaum, U., A. Ferrandez and A. Lanas (2010). "Cost-effectiveness of colorectal cancer screening in high-risk Spanish patients: use of a validated model to inform public policy." Cancer Epidemiol Biomarkers Prev 19(11): 2765-2776. PMCID: 3159034.
  121. Kelley, R. K. and A. P. Venook (2010). "Nonadherence to imatinib during an economic downturn." N Engl J Med 363(6): 596-598.
  122. Kelley, R. K. (2010). "What clinicians need to know about molecular markers in solid tumors. MedscapeCME Oncology. ." Retrieved 1/12/2015, 2015, from
  123. Johnson, F. R., S. Ozdemir and K. A. Phillips (2010). "Effects of simplifying choice tasks on estimates of taste heterogeneity in stated-choice surveys." Soc Sci Med 70(2): 183-190. PMCID: 3152257.
  124. Elkin, E. B. and P. B. Bach (2010). "Cancer's next frontier: addressing high and increasing costs." JAMA 303(11): 1086-1087. PMCID: 3647336.
  125. Cheung, E. L., A. D. Olson, T. M. Yu, P. Z. Han and M. S. Beattie (2010). "Communication of BRCA results and family testing in 1,103 high-risk women." Cancer Epidemiol Biomarkers Prev 19(9): 2211-2219. PMCID: 3207738.
  126. Bowen, D. J., J. Harris, C. M. Jorgensen, M. F. Myers and A. Kuniyuki (2010). "Socioeconomic influences on the effects of a genetic testing direct-to-consumer marketing campaign." Public Health Genomics 13(3): 131-142.
  127. Wideroff, L., K. A. Phillips, G. Randhawa, A. Ambs, K. Armstrong, C. L. Bennett, M. L. Brown, M. S. Donaldson, M. Follen, S. J. Goldie, R. A. Hiatt, M. J. Khoury, G. Lewis, H. L. McLeod, M. Piper, I. Powell, D. Schrag, K. A. Schulman and J. Scott (2009). "A health services research agenda for cellular, molecular and genomic technologies in cancer care." Public Health Genomics 12(4): 233-244. PMCID: 2844634.
  128. Shaukat, A., M. Parekh, J. Lipscomb and U. Ladabaum (2009). "Can calcium chemoprevention of adenoma recurrence substitute or serve as an adjunct for colonoscopic surveillance?" Int J Technol Assess Health Care 25(2): 222-231. PMCID: 2972652.
  129. Phillips, K. A., D. A. Marshall, J. S. Haas, E. B. Elkin, S. Y. Liang, M. J. Hassett, I. Ferrusi, J. E. Brock and S. L. Van Bebber (2009). "Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients." Cancer 115(22): 5166-5174. PMCID: 2783254.
  130. Marshall, D. A., F. R. Johnson, N. A. Kulin, S. Ozdemir, J. M. Walsh, J. K. Marshall, S. Van Bebber and K. A. Phillips (2009). "How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey." Health Econ 18(12): 1420-1439. PMCID: 3964796.
  131. Marshall, D. A. and M. Hux (2009). "Design and analysis issues for economic analysis alongside clinical trials." Med Care 47(7 Suppl 1): S14-20.
  132. Liang, S. Y., J. S. Haas and K. A. Phillips (2009). "Medicare formulary coverage for top-selling biologics." Nat Biotechnol 27(12): 1082-1084. PMCID: 2845541.
  133. Ikediobi, O. N., J. Shin, R. L. Nussbaum, K. A. Phillips, J. M. Walsh, U. Ladabaum and D. Marshall (2009). "Addressing the challenges of the clinical application of pharmacogenetic testing." Clin Pharmacol Ther 86(1): 28-31. PMCID: 2910521.
  134. Hay, J., J. N. Harris, E. A. Waters, M. F. Clayton, L. Ellington, A. D. Abernethy and H. Prayor-Patterson (2009). "Personal communication in primary and secondary cancer prevention: evolving discussions, emerging challenges." J Health Commun 14 Suppl 1: 18-29.
  135. Harris, J. N., D. J. Bowen, A. Kuniyuki, L. McIntosh, L. M. FitzGerald, E. A. Ostrander and J. L. Stanford (2009). "Interest in genetic testing among affected men from hereditary prostate cancer families and their unaffected male relatives." Genet Med 11(5): 344-355. PMCID: 2683189.
  136. Harris, J., D. J. Bowen, H. Badr, P. Hannon, J. Hay and K. Regan Sterba (2009). "Family communication during the cancer experience." J Health Commun 14 Suppl 1: 76-84.
  137. Ferrusi, I. L., D. A. Marshall, N. A. Kulin, N. B. Leighl and K. A. Phillips (2009). "Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses." Per Med 6(2): 193-215. PMCID: 2910630.
  138. Afable-Munsuz, A., S. Y. Liang, N. A. Ponce and J. M. Walsh (2009). "Acculturation and colorectal cancer screening among older Latino adults: differential associations by national origin." J Gen Intern Med 24(8): 963-970. PMCID: 2710471.
  139. Phillips, K. A., S. Y. Liang and S. Van Bebber (2008). "Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value." Curr Opin Mol Ther 10(3): 260-266. PMCID: 2910510.
  140. Phillips, K. A. (2008). "Closing the evidence gap in the use of emerging testing technologies in clinical practice." JAMA 300(21): 2542-2544. PMCID: 2910511.
  141. Payne, K., W. G. Newman, D. Gurwitz, D. Ibarreta and K. A. Phillips (2008). "TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’?" Personalized Medicine 6(1): 103-113.
  142. Parekh, M., A. M. Fendrick and U. Ladabaum (2008). "As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia." Aliment Pharmacol Ther 27(8): 697-712. PMCID: 3170173.

Learn more about our work

Subscribe to our newsletter by emailing [email protected].